{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:05:32Z","timestamp":1794197132209,"version":"4.8.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2016,4,12]]},"abstract":"<jats:p>\n                    Vanutide cridificar (ACC-001), an immunotherapeutic vaccine, is a potentially disease-modifying therapy that aims to reduce brain amyloid-\u03b2 (A\u03b2) plaques in patients with Alzheimer\u2019s disease (AD). ACC-001 was evaluated in two phase 2a, multicenter, randomized, third party\u2013unblinded, placebo-controlled, multiple ascending\u2013dose studies of ACC-001 (3\u03bcg, 10\u03bcg, 30\u03bcg) with and without QS-21 adjuvant that enrolled patients with mild-to-moderate AD (\n                    <jats:italic>n<\/jats:italic>\n                    \u200a=\u200a245). Patients were treated with up to five doses of study vaccine or placebo and followed for safety and tolerability (primary objective) and anti-A\u03b2 IgG immunogenicity (secondary objective) up to 12 months after the last vaccination. Exploratory assessments included cognitive\/functional measures, brain magnetic resonance imaging (MRI) volumetry, and pharmacodynamic markers in plasma and cerebrospinal fluid (CSF). The most frequent treatment-emergent adverse events (\u226510%) were local injection reactions and headache. Amyloid-related imaging abnormalities with vasogenic edema occurred in two (0.8%) patients (ACC-001 30\u03bcg + QS-21; ACC-001 10\u03bcg). ACC-001 + QS-21 elicited consistently higher peak and sustained anti-A\u03b2 IgG titers compared with ACC-001 alone. Plasma A\u03b2\n                    <jats:sub>x\u201340<\/jats:sub>\n                    was significantly higher in all ACC-001 + QS-21 groups versus placebo (weeks 16\u201356), with no evidence of dose response. Exploratory cognitive evaluations, volumetric brain MRI, and CSF biomarkers did not show differences or trends between treatment groups and placebo. ACC-001 with or without QS-21 adjuvant has an acceptable safety profile in patients with mild-to-moderate AD.\n                  <\/jats:p>","DOI":"10.3233\/jad-150376","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T12:08:28Z","timestamp":1460462908000},"page":"1131-1143","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":99,"title":["Two Phase 2 Multiple Ascending\u2013Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"51","author":[{"given":"Florence","family":"Pasquier","sequence":"first","affiliation":[{"name":"Inserm U1171, Memory clinic of CHU and University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Sadowsky","sequence":"additional","affiliation":[{"name":"Premiere Research Institute, Palm Beach Neurology, Nova SE University, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Holstein","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine R&amp;D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislaine Le Prince","family":"Leterme","sequence":"additional","affiliation":[{"name":"Pfizer Global Research and Development, Paris cedex 14 \u2013 France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Peng","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine R&amp;D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Jackson","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine R&amp;D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick C.","family":"Fox","sequence":"additional","affiliation":[{"name":"Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzeera","family":"Ketter","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enchi","family":"Liu","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Ryan","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine R&amp;D, Collegeville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ACC-001 (QS-21) Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,3]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a004457"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3505"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn938"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000113700"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2004.tb00493.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148590.39911.DF"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.4.583"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61075-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-010-0719-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq056"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159740.16984.3C"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxg049"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.1333"},{"key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jalz.2013.05.564","article-title":"Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer\u2019s disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial","volume":"9","author":"Arai H","year":"2013","unstructured":"AraiH, SuzukiH, YoshiyamaT, LobelloK, PengY, LiuE, KetterN, MargolinR, JacksonN, FujimotoY (2013) Safety, tolerability and immunogenicity of an immunotherapeutic vaccine (vanutide cridificar [ACC-001]) and the QS-21 adjuvant in Japanese individuals with mild-to-moderate Alzheimer\u2019s disease: A phase IIa, multicenter, randomized, adjuvant and placebo clinical trial. Alzheimers Dement 9, 282.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199601040-00002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb02571.x"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0108-3"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159743.08996.99"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3181c53b00"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70140-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4742-11.2012"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.90"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1313943"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-150376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-150376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-150376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:27Z","timestamp":1777370547000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-150376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4,12]]}},"alternative-id":["10.3233\/JAD-150376"],"URL":"https:\/\/doi.org\/10.3233\/jad-150376","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}